A retrospective clinical research of relapsed organizing pneumonia

Yamagishi, Toshiyuki; Kodaka, Norio; Watanabe, Kazuo; Nakano, Chihiro; Oshio, Takeshi; Niitsuma, Kumiko; Shimada, Nagashige; Matsuse, Hiroto

doi:10.4103/atm.atm_311_19

Cited by 8 publications

(3 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared with conventional ventilation, initiation of V-V ECMO reduced mortality (65% to 45%), such as young patients with fewer comorbidities, when started within seven days after intubation [ 26 ]. Although most contraindications are relative under normal circumstances, patients with a young age or failure of no more than one organ should be given priority for ECMO during a pandemic, when supplies and equipment are limited [ 27 ]. ECMO should be considered for SARS-CoV-2-induced SOP in the late phase of infection, since OP-related respiratory failure is usually reversible [ 28 , 29 ].…”

Section: Discussionmentioning

confidence: 99%

“…Several serum biomarkers of OP severity have been reported, including KL-6, SP-A, SP-D, and LDH, but useful biomarkers have not been reported to detect SOP due to COVID-19 to date [ 27 , 30 ]. Yamagishi et al showed that OP with high serum concentrations of SP-D relapsed more frequently than with low SP-D concentrations [ 27 ]. A recent case report by Horii et al identified KL-6 and SP-D as possible biomarkers to evaluate SOP during COVID-19 treatment [ 28 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Extracorporeal Membrane Oxygenation for Secondary Organizing Pneumonia after Severe SARS-CoV-2 Infection: A Case Report

et al. 2021

View full text Add to dashboard Cite

(Background) COVID-19 is caused by SARS-CoV-2 infection and may result in unfavorable outcomes. A recent large-scale study showed that treatment with dexamethasone leads to favorable outcomes in patients with severe COVID-19, and the use of extracorporeal membrane oxygenation (ECMO) has also been shown to improve outcomes. Recently, secondary organizing pneumonia (SOP) has been reported after SARS-CoV-2 infection, but the diagnostic and treatment strategies are still unclear. (Case presentation) Here, we report a patient with severe COVID-19 who developed SOP even after the use of dexamethasone, for whom the introduction of ECMO on the 19th day after hospitalization led to a favorable outcome. (Conclusions) Life-threatening SOP may evolve even after the use of dexamethasone, and the late-phase introduction of ECMO may save such patients with COVID-19.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Extracorporeal Membrane Oxygenation for Secondary Organizing Pneumonia after Severe SARS-CoV-2 Infection: A Case Report

et al. 2021

View full text Add to dashboard Cite

show abstract

“…OP with elevated serum KL-6 may be more severe and unstable [ 8 ]; require treatment with prednisolone [ 9 ], and has a higher frequency of relapse [ 10 ] compared to OP with normal serum KL-6. Patients with OP and elevated serum levels of SP-D had significantly increased serum KL-6 level and a significantly higher relapse rate than those with a normal level of SP-D [ 11 ]. Our patient had elevated SP-D levels, but her KL-6 levels were within the reference range, and her SP-D level rapidly decreased after initiating steroid administration.…”

Section: Discussionmentioning

confidence: 99%

Rapidly progressive organizing pneumonia associated with COVID-19

Horii¹,

Kamada²,

Nakakubo³

et al. 2020

Respiratory Medicine Case Reports

View full text Add to dashboard Cite

We report a case of clinically diagnosed secondary organizing pneumonia (SOP) associated with coronavirus disease 2019 (COVID-19). A 70-year-old woman who had been diagnosed with COVID-19 was admitted to Hokkaido University Hospital. Although her fever, cough, dyspnea, and serum C-reactive protein levels improved, she developed rapidly progressive respiratory failure and computed tomography revealed the development of bilateral lung consolidation. Her dyspnea was relieved, and her oxygenation levels and radiological findings improved after commencing corticosteroid treatment. Blood biomarkers for interstitial lung disease, Krebs von den Lungen-6 (KL-6) and surfactant protein D (SP-D), showed different responses during the clinical course of her disease. Evaluation of serial changes in levels of KL-6 and SP-D may help diagnose and monitor COVID-19-associated organizing pneumonia (OP). Clinicians should be aware that SOP can develop in response to COVID-19 and that these patients may benefit from the use of steroids.

show abstract